Rhythm Pharmaceuticals Inc. 近日披露,其针对Setmelanotide治疗获得性下丘脑肥胖症所提交的补充新药申请,已获得美国食品药品监督管理局设定的处方药使用者付费法案目标日期,定于2026年3月20日。
这一关键时间节点的确立,标志着该疗法在监管审批流程中迈出了重要一步,为公司在罕见代谢疾病领域的研发进展提供了明确的时间表。
Rhythm Pharmaceuticals Inc. 近日披露,其针对Setmelanotide治疗获得性下丘脑肥胖症所提交的补充新药申请,已获得美国食品药品监督管理局设定的处方药使用者付费法案目标日期,定于2026年3月20日。
这一关键时间节点的确立,标志着该疗法在监管审批流程中迈出了重要一步,为公司在罕见代谢疾病领域的研发进展提供了明确的时间表。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.